US 12,226,454 B2
Pharmaceutical compositions and use thereof for relieving anticancer drug resistance and enhancing sensitivity of anticancer drug
Jya-Wei Cheng, Tainan (TW); Hsi-Tsung Cheng, Tainan (TW); Hui-Yuan Yu, Tainan (TW); and Su-Ya Hsu, Tainan (TW)
Assigned to RISE BIOPHARMACEUTICALS INC., Beijing (CN)
Filed by Rise Biopharmaceuticals Inc., Beijing (CN)
Filed on Oct. 30, 2020, as Appl. No. 17/085,480.
Application 17/085,480 is a continuation in part of application No. 17/006,512, filed on Aug. 28, 2020.
Application 17/006,512 is a continuation in part of application No. 15/569,033, abandoned, previously published as PCT/CN2015/008725, filed on Jun. 3, 2015.
Claims priority of provisional application 62/959,553, filed on Jan. 10, 2020.
Claims priority of provisional application 62/927,829, filed on Oct. 30, 2019.
Prior Publication US 2021/0060130 A1, Mar. 4, 2021
Int. Cl. A61K 38/19 (2006.01); A61P 35/00 (2006.01); A61K 31/5377 (2006.01)
CPC A61K 38/195 (2013.01) [A61P 35/00 (2018.01); A61K 31/5377 (2013.01)] 3 Claims
 
1. A method for treating a cancer, comprising:
administering a pharmaceutical composition in a therapeutically effective amount according to a gefitinib-resistant cancer subject in need thereof,
wherein the cancer is resistant to gefitinib,
wherein the cancer is non-small cell lung cancer,
wherein the pharmaceutical composition comprises a chemokine analogue peptide and a medicament,
wherein the chemokine analogue peptide is RISE P-8 as set forth in SEQ ID NO:1,
wherein the medicament comprises gefitinib and a pharmaceutically acceptable buffer, diluent, carrier, adjuvant or excipient.